Co-Diagnostics, Inc. (Co-Dx)

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets diagnostic technologies, specializing in reagents for tests that detect and/or analyze nucleic acid molecules (DNA or RNA). Founded in 2013, the company's mission is to democratize access to molecular diagnostics, aiming to transform healthcare delivery and create a positive global impact by providing robust, high-quality, and affordable polymerase chain reaction (PCR) technology, particularly in underserved regions worldwide. Co-Diagnostics is headquartered in Salt Lake City, Utah, United States.

The company's key offerings include its patented Co-Primers™ technology, which is utilized for innovation in disease detection and life sciences research. They provide Logix Smart® PCR tests for various infectious diseases, such as COVID-19, tuberculosis, HPV, mpox, and H5N1. Co-Diagnostics is also developing the Co-Dx PCR Pro™ instrument and associated test kits, designed for at-home and point-of-care real-time PCR testing. Beyond diagnostic products, the company offers software solutions like CoDx™ Software for PCR assay design and cloud-based data management, and engages in licensing its proprietary technologies. Their market segments include infectious diseases and genetic disorders, with a strategic focus on global markets, including Latin America, Asia, and Africa.

Recent notable developments for Co-Diagnostics include advancing its Latin American commercialization strategy for the Co-Dx™ PCR Pro® platform through a distribution agreement in Mexico in June 2026. The company is also developing an Ebola PCR assay strategy in collaboration with its joint venture, CoSara. In May 2026, its joint venture CoMira finalized a lease for a manufacturing facility in Saudi Arabia. Leadership includes Dwight Egan as CEO, with Richard Abbott appointed President in April 2024, alongside David Nielsen as COO, Christopher Thurston as CTO, and Seth Egan as CCO. Co-Diagnostics established an AI business unit in November 2025 to integrate artificial intelligence into its Co-Dx™ Primer Ai™ platform. The company aims to enhance global health by making high-quality, affordable PCR diagnostics widely accessible, including at point-of-care and at-home settings.